Amplitude Surgical – 2022-23 Annual Results
Sales of €100.2 Million and EBITDA of €26.1 Million - Seite 2
General & Administrative costs
13.3
11.5
15.4%
Research & Development costs
1.8
1.8
-3.3%
EBITDA
26.1
22.0
18.7%
as a % of sales
26.1%
25.1%
+95 bps
Recurring operating profit/loss
10.3
6.8
Non-recurring operating income and expenses
-2.3
-1.8
Operating profit/loss
8.0
4.9
Financial profit/loss
-14.0
-6.6
Current and deferred tax
-0.8
-1.2
Profit/loss from discontinued activities, after tax
45.3
-2.0
Net profit/loss - Group share
39.2
-4.4
Net financial debt
69.3
118.0
Net cash position at end of period
37.2
21.0